These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36164668)

  • 1. Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer.
    Wang S; Zhang C; Xu Z; Chen MH; Yu H; Wang L; Liu R
    Prostate; 2023 Jan; 83(1):97-108. PubMed ID: 36164668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
    Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ
    J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
    Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
    Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
    Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
    Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice.
    Kladney RD; Cardiff RD; Kwiatkowski DJ; Chiang GG; Weber JD; Arbeit JM; Lu ZH
    Cancer Res; 2010 Nov; 70(21):8937-47. PubMed ID: 20940396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
    Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
    Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.
    Gao Y; Gartenhaus RB; Lapidus RG; Hussain A; Zhang Y; Wang X; Dan HC
    Mol Cancer Res; 2015 Dec; 13(12):1602-14. PubMed ID: 26374334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
    Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
    Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
    Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
    J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells.
    Lee SH; Johnson D; Luong R; Sun Z
    J Biol Chem; 2015 Jan; 290(5):2759-68. PubMed ID: 25527506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
    Robb VA; Astrinidis A; Henske EP
    Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer.
    Sutera P; Kim J; Kumar R; Deek RA; Stephenson R; Mayer T; Saraiya B; Ghodoussipour S; Jang T; Golombos D; Packiam V; Ennis R; Hathout L; Jabbour SK; Guler O; Onal C; Tran PT; Deek MP
    Prostate; 2024 Oct; 84(14):1301-1308. PubMed ID: 39021052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
    Miyazaki M; McCarthy JJ; Esser KA
    FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.
    Yang CS; Melhuish TA; Spencer A; Ni L; Hao Y; Jividen K; Harris TE; Snow C; Frierson HF; Wotton D; Paschal BM
    Prostate; 2017 Nov; 77(15):1452-1467. PubMed ID: 28875501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.
    Zhang H; Bajraszewski N; Wu E; Wang H; Moseman AP; Dabora SL; Griffin JD; Kwiatkowski DJ
    J Clin Invest; 2007 Mar; 117(3):730-8. PubMed ID: 17290308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation.
    Bilir B; Osunkoya AO; Wiles WG; Sannigrahi S; Lefebvre V; Metzger D; Spyropoulos DD; Martin WD; Moreno CS
    Cancer Res; 2016 Mar; 76(5):1112-21. PubMed ID: 26701805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Akt-mTOR tango and its relevance to cancer.
    Hay N
    Cancer Cell; 2005 Sep; 8(3):179-83. PubMed ID: 16169463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis.
    Tanwar PS; Kaneko-Tarui T; Zhang L; Teixeira JM
    Hum Mol Genet; 2012 Oct; 21(20):4394-405. PubMed ID: 22791749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs.
    Wan L; Wang Y; Li J; Wang Y; Zhang H
    Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(11):1637-1647. PubMed ID: 36331296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC.
    Wu L; Yi B; Wei S; Rao D; He Y; Naik G; Bae S; Liu XM; Yang WH; Sonpavde G; Liu R; Wang L
    Cancer Res; 2019 Apr; 79(7):1413-1425. PubMed ID: 30733194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.